LNAIHealthcare · BiotechnologyLNAI Stock Forecast: Lunai Bioworks, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 1 Aug 2026 — in the lower half.
LNAI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Lunai Bioworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (100): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Lunai Bioworks, Inc. — and when they’d sell — is the membership.
LNAI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LNAI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LNAI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Lunai Bioworks, Inc. (LNAI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 420.0×
- Price / book
- −0.6×
- EV / EBITDA
- −0.7×
Cheaper than 75% of US stocks
Cheaper than 2% of US stocks
Cheaper than 94% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 100.0%
- Operating margin
- −6815.3%
- Net margin
- 0.0%
Higher than 99% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
- Return on equity
- −325.5%
- Return on assets
- −9.6%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 27% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LNAI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNAI appears on the weeks it earns a place.
Frequently asked questions about LNAI stock
How does Ticker Nerd's model rank LNAI?
As at 1 Aug 2026, Lunai Bioworks, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (100 of 100).
What is the LNAI stock forecast for 2030?
No analyst covering Lunai Bioworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNAI are extrapolating price history, which says nothing about the business.
How has LNAI stock performed over the past year?
Lunai Bioworks, Inc. returned -88.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lunai Bioworks, Inc. do?
Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products.
About Lunai Bioworks, Inc.
Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products. The company integrates artificial intelligence, genomics, and living biological systems to decode disease mechanisms and identify therapeutic targets. Its pipeline includes genetically modified dendritic cell therapeutic vaccines, such as RENB-DC11 for pancreatic cancer and RENB-DC20 for breast cancer treatment. Lunai Bioworks operates through multiple segments, including RENB, BioSymetrics, and RENC. The company employs proprietary AI platforms combined with zebrafish models to uncover drug efficacy, safety profiles, and clinical biomarkers that traditional research methods may overlook. By integrating phenotypic, proteomic, and genomic data, Lunai Bioworks aims to create clear pathways from disease discovery to patient benefit, focusing on precision medicine approaches for oncology and other therapeutic areas. Headquartered in Los Angeles, California, the company serves both the United States and Netherlands markets.
CEO Mr. David H. Weinstein · 29 employees · United States · https://www.lunaibioworks.com